Franco-Indian Pharmaceuticals Pvt. Ltd., a name that stands for quality and innovation, is one of the major players in the Pharmaceutical Industry in India.
Our innovative, value added products improve the quality of life of people and ease their sufferings and help them to enjoy, longer, healthier and more productive lives.?
Franco-Indian?s strongest attributes are the unwavering focus on ethics, transparency, corporate culture, quality of products, contribution to society and commitment to growth.?
Franco-Indian is a company that strives to achieve excellence through motivating and empowering it's employees. The HR system is designed with transparency and feedback as the primary pivots of employee evaluation and growth.?
Given the fact that the company is operating in a knowledge-based industry, Franco-Indian lays a great stress on knowledge management and development as a knowledge-based company through dedicated training programmes for all members of sales, marketing and research teams.
Franco-Indian, as a consequence of its better HR practices, has not only attracted some of the finest talents in the industry, but also retained those talents contrary to the common industry practices. ???
? In 1961, FRANCO-INDIAN reached an agreement with LABORATOIRES GRIMAULT,FRANCE to market their specialties in INDIA and subsequently started its own manufacturing unit in MUMBAI. This Company over the years has developed expertise in the manufacture of products for Diabetes, for the treatment of Vitiligo, Psoriasis & Hepatic disorders.?
Today, LABORATOIRES GRIFFON (earlier LABORATOIRES GRIMAULT) enjoys a major share in Therapeutic segments like Anti- diabetics, Hepatoprotective and Dermatology.
This Company has manufacturing units at?KOLKATA?in West Bengal, SAHIBABAD in Uttar Pradesh and CHENNAI? in? TamilNadu. WARDEX?PHARMACEUTICALS?? PRIVATE?? LIMITED was established with a view to meet the increasing demand of DEXORANGE SYRUP, the leading Hematinic and also the brand leader in this segment.
The objective of this Company was to ensure availability of DEXORANGE SYRUP all over India, keeping logistics of the country in mind. Besides the Anti-anaemic segment, WARDEX PHARMACEUTICALS has a strong presence in the field of Bronchodilators and Cough and Cold preparations with their products GRILINCTUS and GRILINCTUS BM SYP/TABS/PAED.SYP. GRILINCTUS BM is a brand leader in it's segment.
With a view to keep in mind good manufacturing practices as a fundamental rule, this Company was established as a manufacturing unit at CHENNAI and over the years FRANCO-INDIAN REMEDIES has emerged as a successful tablet and liquid manufacturing company.
Today,?FRANCO-INDIAN PHARMACEUTICALS PRIVATE LIMITED, besides having its own manufacturing unit at MUMBAI, also utilizes the manufacturing facilities of LABORATOIRES GRIFFON , WARDEX PHARMACEUTICALS and FRANCO-INDIAN REMEDIES and have thus achieved a respectable ranking in the Pharmaceutical Industry of India.
Over the years?FRANCO-INDIAN PHARMACEUTICALS PRIVATE LIMITED?has grown in stature and as on today has over 1200 Employees inclusive of 400 Marketing Professionals, together with a Distribution network of 18 C
Team / Manpower
The Company is managed by :
Chairman Mr. Michel Postel
Managing Director Mr. Pascal Postel
Directors Mr. E. J. Desouza (Executive Director) Mr. L. B. Yadav Mr. A.G. Sonde Dr. S.D. Sabnis Mr. S.G. Shanbhag Mr. J. O. Chavda Mr. A. K. Chatterjee
Year of Establishment
Nature of Business
Posted on: [26-MAR-10]
Happenings / News / Press Coverage
GUT MICROBES GIVE US CLUES TO OBESITY CAUSE AND TREATMENT
US scientists have discovered that "gut microbes" - bacteria that live in our digestive tract - could be powerful clues to the cause and treatment of obesity.
This remarkable news was published in Nature this week and conducted at Washington University School of Medicine in St. Louis.
The clue lies in the relative abundance of two major families of intestinal bacteria: Firmicutes and Bacteroidetes. These make up 90 per cent of the bacteria in the gut of humans, and, coincidentally, white mice.
Researchers in the first of two parallel studies found that as obese people lose weight, the balance between the Firmicutes and the Bacteroidetes changes - the latter increasing in abundance as an overweight person gets slimmer. (It would seem that the microbes ending in "cute" are perhaps not as lovable as their name implies!).
The second study was conducted in a neighbouring lab using white mice. Here, researchers discovered that the bacteria in the guts of obese white mice were more efficient at extracting calories from complex carbohydrates than the bacteria in the guts of slimmer mice.
Also, in an earlier study, they had shown that the guts of obese mice had the same depletion of Bacteroidetes as found in the guts of the obese humans.
This means that you could have two guys eating the same amount of food (i.e. consuming the same calories) each day, and doing the same amount of exercise (i.e. burning equal number of calories) but over the course of several years, one gradually gets fatter and the other stays the same. Why? Because the one who stays the same has more Bacteroidetes in his gut, extracting fewer calories from the same amount of food.
The poor guy who gets fatter has a more efficient calorie grabber in his gut, and the excess gets stored as fat - putting him at higher risk of eventually becoming obese.
Trillions of "friendly" gut bacteria digest the food we eat by breaking down complex molecules like polysaccharides (complex carbs found in fruit, vegetables and grains) into simple sugars for energy. The excess is converted to fat for longer term storage. However, these studies suggest that the simple equation (calorie value of food intake) - (energy we use) equals (the fat we store), is different for different people.
These studies form part of a growing body of research revealing fascinating new insights into what we are made of and what makes us tick.
We used to think that the human body was a collection of cells with the same DNA imprint - like a unique bar code for each person. However, within us, in our guts, lie communities of microbes that outnumber our cells by 10 to 1, and, according to the researchers behind these two studies, "they may contain 100 times more genes than our own human genome".
The researchers suggest that intestinal bacteria could become "biomarkers, mediators and potential therapeutic targets" in the fight against obesity.
GENE CHIP DISCOVERY MAY LEAD TO INDIVIDUALIZED TREATMENT FOR FIVE HEREDITARY LIVER DISEASES
Researchers at Cincinnati Children's Hospital Medical Center have developed the first gene chip to use in the early diagnosis of at least five hereditary liver diseases, to detect genetic causes of jaundice in children and adults, and potentially to lead to personalized treatment options.
Dealing and supplying of active pharmaceutical ingredients, lumifantrine tablets, pharmaceutical capsule, betamethasone salts, pharmaceutical chemical, anti asthmatic formulations, pharmaceutical formulations and artesunate tablets.
Manufacturing and supply of pharmaceutical medicines that includes pharmaceutical capsules, ofloxacin capsules and ciprofloxacin capsules, pharmaceutical tablets, ciprofloxacin tablets and ofloxacin tablets in Karnataka.